CAR-T Cells in the Treatment of Malignant Hematological Tumors

Hebei Senlang Biotechnology

Status

Enrolling

Conditions

Leukemia, B-cell

Lymphoma, B-Cell

Leukemia, T-Cell

Multiple Myeloma

Treatments

Biological: CAR-T

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT05619861

2022/11/09

Details and patient eligibility

About

To evaluate the safety of autologous CAR-T cell injection in the treatment of recurrent and refractory hematopoietic and lymphoid tissue tumors

Full description

Main research objective: To evaluate the safety of autologous CAR-T cell injection in the treatment of recurrent and refractory hematopoietic and lymphoid tissue tumors. Secondary research objective: To investigate the efficacy and cytodynamic characteristics of autologous CAR-T cell injection in the treatment of recurrent and refractory hematopoietic and lymphoid tissue tumors

Enrollment

20 estimated patients

Sex

All

Ages

14 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

With the consent of himself or the legal guardian and the signed informed consent, he is willing and able to comply with the planned visit, research and treatment, laboratory examination and other test procedures; Clinical Study of CAR-T Technique in the Treatment of Recurrent and Refractory Hematopoietic and Lymphatic Tumor
Patients with recurrent and refractory hematopoiesis and lymphoid tissue tumors determined by clinical diagnosis;
Age 14-70 (including boundary value), both male and female;
Subjects with a physical status of 0~2 in the American Eastern Oncology Collaboration Group (ECOG);
The results of treatment related antigens were positive;
The expected life span is more than 3 months from the date of signing the informed consent;